Subscribe

Stay Informed. Stay Ahead.

Subscribe to receive curated updates, expert insights, and practical education—delivered straight to your inbox.

Get timely coverage on new approvals, case-based discussions, conference highlights, and practical tools for everyday practice in community oncology and hematology.

Subscribe
*
Skip to main content
OncUpdates
  • Conferences
    • ESMO
    • WCLC
    • ASCO
  • Videos & Podcasts
    • Challenging Cases
      • Hematology
      • Lung Cancer
    • New Approvals
      • GI
      • GU
      • Lung Cancer
    • Tox Check
      • GI
      • GU
      • Lung Cancer
      • Breast Cancer
    • Treatment Algorithms
      • Hematology
      • Lung Cancer
      • Ovarian Cancer
  • Articles
    • Breast Cancer
    • GU Oncology
    • GI Oncology
    • Hematology
    • Lung Cancer
      • NSCLC
      • SCLC
  • Clinical Insights
    • Bladder Cancer
    • Lung Cancer
      • SCLC
      • NSCLC
  • Conferences
    • ESMO
    • WCLC
    • ASCO
  • Videos & Podcasts
    • Challenging Cases
      • Hematology
      • Lung Cancer
    • New Approvals
      • GI
      • GU
      • Lung Cancer
    • Tox Check
      • GI
      • GU
      • Lung Cancer
      • Breast Cancer
    • Treatment Algorithms
      • Hematology
      • Lung Cancer
      • Ovarian Cancer
  • Articles
    • Breast Cancer
    • GU Oncology
    • GI Oncology
    • Hematology
    • Lung Cancer
      • NSCLC
      • SCLC
  • Clinical Insights
    • Bladder Cancer
    • Lung Cancer
      • SCLC
      • NSCLC

Explore Videos, Articles & More

NSCLC

Power Your Practice with Smarter Oncology Insights

Home / Conferences / ASCO / Lung Cancer / NSCLC
Innovación dirigida: datopotamab deruxtecan en el tratamiento del cáncer de pulmón no microcítico avanzado
Innovación dirigida: datopotamab deruxtecan en el tratamiento del cáncer de pulmón no microcítico avanzado

Coral Olazagasti, MD, Narjust Florez, MD, FASCO

Datopotamab Deruxtecan in NSCLC: A Closer Look at TROP2-Targeted Therapy
Datopotamab Deruxtecan in NSCLC: A Closer Look at TROP2-Targeted Therapy

Coral Olazagasti, MD, Narjust Florez, MD, FASCO

ASCO 2025: Key Clinical Trials in Resectable NSCLC
ASCO 2025: Key Clinical Trials in Resectable NSCLC

Eric Singhi, MD, Mitchell Alexander Parma, MD

Tailoring Treatment for Patients With EGFR-Positive NSCLC
Tailoring Treatment for Patients With EGFR-Positive NSCLC

Chinmay Jani, MD, Coral Olazagasti, MD

OncUpdates

Empowering oncology professionals with The latest insights, breakthroughs, And expert opinions

Quick Links

  • About Us
  • Contact Us
  • Follow on X
  • Follow on LinkedIn

Legal

  • Terms of Use
  • Privacy Policy
  • Cookie Settings

Subscribe to Our Newsletters


Property of SignifyMD LLC, All Rights Reserved 2025 SignifyMD LLC PO Box 512, Brielle, NJ 08730


Oncology Resources | Hematology Support | Community Oncology